China Isotope & Radiation Corporation (CIRC, 01763) has released its eighth Environmental, Social and Governance (ESG) Report, covering the 2025 financial year (1 Jan–31 Dec 2025).
Key financial and strategic highlights • Overseas revenue rose 70.11% year-on-year, driven by new irradiation projects in Bangladesh, Peru and other markets, the launch of breath-test products in 12 countries and Europe’s first import of China-made carbon-14 products. • CIRC’s Hong Kong-listed shares gained 103% during 2025, outperforming the Hang Seng Composite Index by 28 ppts and the Hang Seng Healthcare Index by 65 ppts. • All 170 measures under the Group’s reform deepening programme were completed; the company retained an “A” rating in China National Nuclear Corporation’s annual assessment and maintained “Benchmark” status in SASAC’s Science & Technology Reform evaluation.
Operational and innovation milestones • Two radiopharmaceuticals, led by Gallium-68 Dotatate Injection, were submitted for marketing approval; six additional candidates, including Lutetium-177 Oxodotreotide, entered Phase III trials. • A boron neutron capture therapy drug obtained clinical-trial approval, while high-abundance 13CO gas and carbon-13 urea produced in-house marked full domestic control of the carbon stable-isotope value chain. • The AI Radiotherapy Robot “CyberKnife S7” and the Suπ One 13C Breath Analyzer secured market clearance; 25 Tomo units won domestic tenders, and CyberKnife systems accounted for 73% of China’s Class A radiotherapy equipment permits.
Governance and compliance • A three-tier ESG governance structure is in place; compliance management system certification was achieved under ISO 37301 and GB/T 35770-2022, with a 99.72% remediation rate for internal-control issues. • No cases of bribery, fraud or money-laundering were reported; anti-corruption training covered directors and staff, and multiple whistle-blowing channels remain active.
Environmental performance • Greenhouse-gas emissions fell 2.26% to 26,622 tCO2e (Scope 1: 2,740 tCO2e; Scope 2: 23,882 tCO2e). • Energy consumption reached 6,148.53 tonnes of standard coal equivalent; CIRC expanded rooftop solar generation and installed an energy-monitoring platform across nine legal entities. • Wastewater, waste-gas and solid-waste compliance rates held at 100%; two subsidiaries obtained ISO 14001:2015 certification.
Human capital • Total headcount rose to 3,578, with female staff representing 32%. • The company introduced 11 high-level experts, appointed 10 new chief experts/technical leaders and delivered 20 focused training programmes, achieving 100% employee-training coverage. • No work-related fatalities or lost-time incidents were recorded in 2025.
Social contribution • Rural-revitalisation spending reached RMB 1.70 million—22% above target—including medical-equipment donations worth RMB 1.50 million to Baihe County, Shaanxi. • CIRC hosted the IAEA regional training course on radiotracer applications, while its first agricultural gamma-irradiation station project in Peru extended the group’s footprint to Latin America.
The report underscores CIRC’s strategic focus on nuclear-technology innovation, stringent governance and low-carbon operations, positioning the company as a leading player in China’s nuclear medicine and irradiation sectors.
Comments